Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH)

British Journal of Pharmacology

Volumn 163, Issue 5, 2011, Pages 891-907

  Ventura, S ^a   Oliver, V L ^a   White, C W ^a   Xie, J H ^a   Haynes, J M ^a   Exintaris, B ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

5 reductase inhibitors; adenosine; adrenoceptors; cannabinoids; LHRH antagonists; phosphodiesterase inhibitors; prostaglandin E 2; prostate contractility; Rho kinase inhibitors; Vitamin D3 analogues

Indexed keywords

ADENOSINE RECEPTOR STIMULATING AGENT; ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CETRORELIX; DUTASTERIDE; ENDOTHELIN RECEPTOR ANTAGONIST; FINASTERIDE; MEPYRAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE DONOR; PEPTIDE DERIVATIVE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E2; PURINERGIC P2X RECEPTOR ANTAGONIST; PURINERGIC P2X1 RECEPTOR ANTAGONIST; RHO KINASE INHIBITOR; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TACHYKININ RECEPTOR ANTAGONIST; TADALAFIL; TAMSULOSIN; TOLTERODINE; UDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL;

CELL PROLIFERATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EJACULATION DISORDER; HUMAN; IMPOTENCE; LIBIDO DISORDER; MALE GENITAL SYSTEM FUNCTION; NONHUMAN; OVERACTIVE BLADDER; PACEMAKER NERVE CELL; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REVIEW; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE RELAXATION; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL RESECTION; URETHRA OBSTRUCTION;

ANIMALS; DRUG DISCOVERY; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PROSTATIC HYPERPLASIA;

EID: 79958836057     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01332.x     Document Type: Review

References (182)

1. Abrams P, Kaplan S, De Koning Gans HJ, Millard R, (2006). Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175: 999-1004. (Pubitemid 43200054)
2. Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP, (2002). Lysophosphatidic acid stimulates proliferation of cultured smooth muscle cells from human BPH tissue: sildenafil and papaverin generate inhibition. Prostate 51: 50-58. (Pubitemid 34274860)
3. Athanasopoulos A, (2010). Antimuscarinics and bladder outlet obstruction: from a contraindication to an indication? Neurourol Urodyn 29 (Suppl. 1): S46-S50.
4. Auffenberg GB, Helfand BT, McVary KT, (2009). Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 36: 443-459.
5. Aumuller G, Enderle-Schmitt U, Seitz J, Muntzing J, Chandler JA, (1987). Ultrastructure and immunohistochemistry of the lateral prostate in aged rats. Prostate 10: 245-256. (Pubitemid 17085097)
6. Avellar MC, Lazari MF, Porto CS, (2009). Expression and function of G-protein-coupled receptors in the male reproductive tract. An Acad Bras Cienc 81: 321-344.
7. Banks FC, Knight GE, Calvert RC, Thompson CS, Morgan RJ, Burnstock G, (2006). The purinergic component of human vas deferens contraction. Fertil Steril 85: 932-939.
8. Bergstrom S, Carlson LA, Weeks JR, (1968). The prostaglandins: a family of biologically active lipids. Pharmacol Rev 20: 1-48.
9. Berkowitz DE, Nardone NA, Smiley RM, Price DT, Kreutter DK, Fremeau RT, et al,. (1995). Distribution of beta 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289: 223-228.
10. Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K, (1997). Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 33: 1-8. (Pubitemid 27381587)
11. Buljubasich R, Ventura S, (2004). Adenosine 5′-triphosphate and noradrenaline are excitatory cotransmitters to the fibromuscular stroma of the guinea pig prostate gland. Eur J Pharmacol 499: 335-344. (Pubitemid 39233673)
12. Buljubasich S, Lau WA, Pennefather JN, Ventura S, (1999). An immunohistochemical and pharmacological study of tachykinins in the rat and guinea-pig prostate glands. Eur J Pharmacol 380: 137-144. (Pubitemid 29469524)
13. Burnstock G, Knight GE, (2004). Cellular distribution and functions of P2 receptor subtypes in different systems. Int Rev Cytol 240: 31-304. (Pubitemid 39539202)
14. Caine M, Raz S, Zeigler M, (1975). Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 47: 193-202.
15. Carson C, 3rd, Rittmaster R, (2003). The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61: 2-7. (Pubitemid 36349123)
16. Chamberlain PD, Jennings KH, Paul F, Cordell J, Berry A, Holmes SD, et al,. (1999). The tissue distribution of the human beta3-adrenoceptor studied using a monoclonal antibody: direct evidence of the beta3-adrenoceptor in human adipose tissue, atrium and skeletal muscle. Int J Obes Relat Metab Disord 23: 1057-1065. (Pubitemid 29476208)
17. Chapple C, (2010). Antimuscarinics in men with lower urinary tract symptoms suggestive of bladder outlet obstruction due to benign prostatic hyperplasia. Curr Opin Urol 20: 43-48.
18. Chapple CR, Crowe R, Gilpin SA, Gosling J, Burnstock G, (1991). The innervation of the human prostate gland-the changes associated with benign enlargement. J Urol 146: 1637-1644.
19. Chapple CR, Burt RP, Andersson PO, Greengrass P, Wyllie M, Marshall I, (1994). Alpha 1-adrenoceptor subtypes in the human prostate. Br J Urol 74: 585-589. (Pubitemid 24348624)
20. Chueh SC, Guh JH, Chen J, Lai MK, Ko FN, Teng CM, (1996). Inhibition by tamsulosin of tension responses of human hyperplastic prostate to electrical field stimulation. Eur J Pharmacol 305: 177-180. (Pubitemid 26197604)
21. Colli E, Rigatti P, Montorsi F, Artibani W, Petta S, Mondaini N, et al,. (2006). BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol 49: 82-86. (Pubitemid 41789960)
22. Comaru-Schally AM, Brannan W, Schally AV, Colcolough M, Monga M, (1998). Efficacy and safety of luteinizing hormone-releasing hormone antagonist cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab 83: 3826-3831. (Pubitemid 28513557)
23. Cook AL, Haynes JM, (2004). Protein kinase G II-mediated proliferative effects in human cultured prostatic stromal cells. Cell Signal 16: 253-261. (Pubitemid 37441272)
24. Cook AL, Frydenberg M, Haynes JM, (2002). Protein kinase G activation of K(ATP) channels in human-cultured prostatic stromal cells. Cell Signal 14: 1023-1029. (Pubitemid 35279426)
25. Couldwell C, Jackson A, O'Brien H, Chess-Williams R, (1993). Characterization of the alpha 1-adrenoceptors of the rat prostate gland. J Pharm Pharmacol 45: 922-924. (Pubitemid 23310428)
26. Debruyne F, Gres AA, Arustamov DL, (2008). Placebo-controlled dose-ranging phase 2 study of subcutaneously administered LHRH antagonist cetrorelix in patients with symptomatic benign prostatic hyperplasia. Eur Urol 54: 170-177.
27. Debruyne F, Tzvetkov M, Altarac S, Geavlete PA, (2010). Dose-ranging study of the luteinizing hormone-releasing hormone receptor antagonist cetrorelix pamoate in the treatment of patients with symptomatic benign prostatic hyperplasia. Urology 76: 927-933.
28. Delaflotte S, Auguet M, Chabrier PE, (1996). Pharmacological evidence that different alpha 1 adrenoceptor subtypes mediate contraction in rabbit prostate and hypogastric artery. Acta Physiol Scand 158: 241-251. (Pubitemid 26361808)
29. Dey A, Nguyen DT, Lang RJ, Exintaris B, (2009). Spontaneous electrical waveforms in aging guinea pig prostates. J Urol 181: 2797-2805.
30. Dmochowski R, Roehrborn C, Klise S, Xu L, Kaminetsky J, Kraus S, (2010). Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 183: 1092-1097.
31. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M, (1994). Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 54: 4091-4095. (Pubitemid 24258114)
32. Drescher P, Eckert RE, Madsen PO, (1994). Smooth muscle contractility in prostatic hyperplasia: role of cyclic adenosine monophosphate. Prostate 25: 76-80. (Pubitemid 24246108)
33. Eckert RE, Schreier U, Drescher P, Madsen PO, Derouet H, Becht E, et al,. (1995). Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia. Urol Int 54: 6-21.
34. Eckhardt MD, van Venrooij GE, Boon TA, (2001a). Symptoms and quality of life versus age, prostate volume, and urodynamic parameters in 565 strictly selected men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology 57: 695-700.
35. Eckhardt MD, van Venrooij GE, Boon TA, (2001b). Interactions between prostate volume, filling cystometric estimated parameters, and data from pressure-flow studies in 565 men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Neurourol Urodyn 20: 579-590. (Pubitemid 32880421)
36. Eckhardt MD, van Venrooij GE, Boon TA, (2001c). Symptoms, prostate volume, and urodynamic findings in elderly male volunteers without and with LUTS and in patients with LUTS suggestive of benign prostatic hyperplasia. Urology 58: 966-971. (Pubitemid 34017282)
37. Exintaris B, Klemm MF, Lang RJ, (2002). Spontaneous slow wave and contractile activity of the guinea pig prostate. J Urol 168: 315-322. (Pubitemid 34640850)
38. Exintaris B, Nguyen DT, Dey A, Lang RJ, (2006). Spontaneous electrical activity in the prostate gland. Auton Neurosci 126-127: 371-379. (Pubitemid 43816927)
39. Exintaris B, Nguyen DT, Lam M, Lang RJ, (2009). Inositol trisphosphate-dependent Ca stores and mitochondria modulate slow wave activity arising from the smooth muscle cells of the guinea pig prostate gland. Br J Pharmacol 156: 1098-1106.
40. Fair WR, Cordonnier JJ, (1978). The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol 120: 695-698. (Pubitemid 9091399)
41. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, et al,. (2000). Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97: 3702-3707. (Pubitemid 30183366)
42. Fernandez JL, Rivera L, Lopez PG, Recio P, Vela-Navarrete R, Garcia-Sacristan A, (1998). Characterization of the muscarinic receptor mediating contraction of the dog prostate. J Auton Pharmacol 18: 205-211. (Pubitemid 28463932)
43. Fibbi B, Morelli A, Vignozzi L, Filippi S, Chavalmane A, De Vita G, et al,. (2010). Characterization of phosphodiesterase type 5 expression and functional activity in the human male lower urinary tract. J Sex Med 7: 59-69.
44. Fry CH, Meng E, Young JS, (2010). The physiological function of lower urinary tract smooth muscle. Auton Neurosci 154: 3-13.
45. Gallegos PJ, Frazee LA, (2008). Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia. Pharmacotherapy 28: 356-365. (Pubitemid 351328908)
46. Goepel M, Wittmann A, Rubben H, Michel MC, (1997). Comparison of adrenoceptor subtype expression in porcine and human bladder and prostate. Urol Res 25: 199-206. (Pubitemid 27252798)
47. Gonzalez-Barcena D, Vadillo-Buenfil M, Gomez-Orta F, Fuentes Garcia M, Cardenas-Cornejo I, Graef-Sanchez A, et al,. (1994). Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate 24: 84-92. (Pubitemid 24073107)
48. Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, et al,. (2010). Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol 57: 902-910.
49. Gray KT, Ventura S, (2005). Evaluation of the mouse prostate as a suitable model for the study of human prostate function. J Pharmacol Toxicol Methods 51: 41-50. (Pubitemid 41556702)
50. Gray KT, Ventura S, (2006). Alpha1L-adrenoceptors mediate contractions of the isolated mouse prostate. Eur J Pharmacol 540: 155-161. (Pubitemid 43866697)
51. Gray K, Short J, Ventura S, (2008a). The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155: 103-109.
52. Gray KT, Short JL, Ledent C, Ventura S, (2008b). Targeted disruption of the A2A adenosine receptor reduces in-vitro prostate contractility in mature mice. Eur J Pharmacol 592: 151-157.
53. Guh JH, Chueh SC, Ko FN, Teng CM, (1995). Characterization of alpha 1-adrenoceptor subtypes in tension response of human prostate to electrical field stimulation. Br J Pharmacol 115: 142-146.
54. Guh JH, Chueh SC, Hwang TL, Chen J, Teng CM, (1998). Cell proliferation in human prostatic smooth muscle cells involves the modulation of protein kinase C isozymes. Eur J Pharmacol 359: 281-284. (Pubitemid 28513025)
55. Gup DI, Shapiro E, Baumann M, Lepor H, (1989). Contractile properties of human prostate adenomas and the development of infravesical obstruction. Prostate 15: 105-114. (Pubitemid 19262139)
56. Hasan M, Parveen F, Shamsuzzaman AK, Kibria MD, (2007). Comparison of efficacy between Tamsulosin and Finasteride on symptomatic Benign Prostatic Hyperplasia. Mymensingh Med J 16: 154-159.
57. Hashim H, Abrams P, (2010). Emerging drugs for the treatment of benign prostatic obstruction. Expert Opin Emerg Drugs 15: 159-174.
58. Haynes JM, Cook AL, (2006). Protein kinase G-induced activation of K(ATP) channels reduces contractility of human prostate tissue. Prostate 66: 377-385. (Pubitemid 43346948)
59. Haynes JM, Hill SJ, (1997). Beta-adrenoceptor-mediated inhibition of alpha 1-adrenoceptor-mediated and field stimulation-induced contractile responses in the prostate of the guinea pig. Br J Pharmacol 122: 1067-1074. (Pubitemid 27494220)
60. Hedlund H, Andersson KE, Larsson B, (1985). Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate. J Urol 134: 1291-1298. (Pubitemid 16207056)
61. Hedlund P, Ekstrom P, Larsson B, Alm P, Andersson KE, (1997). Heme oxygenase and NO-synthase in the human prostate-relation to adrenergic, cholinergic and peptide-containing nerves. J Auton Nerv Syst 63: 115-126. (Pubitemid 27168871)
62. Hiraoka Y, Ohmura T, Sakamoto S, Hayashi H, Muramatsu I, (1995). Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. J Auton Pharmacol 15: 271-278.
63. Holden CA, McLachlan RI, Pitts M, Cumming R, Wittert G, Agius PA, et al,. (2005). Men in Australia Telephone Survey (MATeS): a national survey of the reproductive health and concerns of middle-aged and older Australian men. Lancet 366: 218-224. (Pubitemid 40981049)
64. Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete RV, (2007). The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 51: 207-215 discussion 215-206.
65. Imajo C, Walden PD, Shapiro E, Doherty AM, Lepor H, (1997). Evaluation of the effect of endothelin-1 and characterization of the selective endothelin a receptor antagonist PD155080 in the prostate. J Urol 158: 253-257. (Pubitemid 27251636)
66. Jen PY, Dixon JS, (1995). Development of peptide-containing nerves in the human fetal prostate gland. J Anat 187: 169-179.
67. Kalodimos PJ, Ventura S, (2001). Beta2-adrenoceptor-mediated inhibition of field stimulation induced contractile responses of the smooth muscle of the rat prostate gland. Eur J Pharmacol 431: 81-89. (Pubitemid 33082155)
68. Kaplan SA, Gonzalez RR, (2007). Phosphodiesterase type 5 inhibitors for the treatment of male lower urinary tract symptoms. Rev Urol 9: 73-77.
69. Kaplan SA, Hatzichristou D, (2007). Open to debate. The motion: PDE5 inhibitors will have a significant role in the treatment of BPH. Eur Urol 52: 1523-1527.
70. Kaplan SA, Gonzalez RR, Te AE, (2007). Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51: 1717-1723. (Pubitemid 46634750)
71. Kedia G, Uckert S, Scheller F, Chigogidze T, Managadze L, Jonas U, et al,. (2006). In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 67: 1292-1297. (Pubitemid 43818055)
72. Kerr KP, (2006). The effect of histamine on field-stimulated contractions of the guinea-pig prostate. Naunyn Schmiedebergs Arch Pharmacol 373: 237-244. (Pubitemid 43829498)
73. Kester RR, Mooppan UM, Gousse AE, Alver JE, Gintautas J, Gulmi FA, et al,. (2003). Pharmacological characterization of isolated human prostate. J Urol 170: 1032-1038. (Pubitemid 36999627)
74. Kitada S, Kumazawa J, (1987). Pharmacological characteristics of smooth muscle in benign prostatic hyperplasia and normal prostatic tissue. J Urol 138: 158-160. (Pubitemid 17094476)
75. Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U, (1999). Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 31: 335-341. (Pubitemid 30041837)
76. Kobayashi S, Tang R, Wang B, Opgenorth T, Langenstroer P, Shapiro E, et al,. (1994). Binding and functional properties of endothelin receptor subtypes in the human prostate. Mol Pharmacol 45: 306-311.
77. Kondo S, Morita T, Tashima Y, (1994). Endothelin receptor density in human hypertrophic and non-hypertrophic prostate tissue. Tohoku J Exp Med 172: 381-384.
78. Kondo S, Morita T, Tashima Y, (1995). Benign prostatic hypertrophy affects the endothelin receptor density in the human urinary bladder and prostate. Urol Int 54: 198-203.
79. Konrad L, Schiemann P, Renneberg H, Wennemuth G, Fini C, Aumuller G, (1998). Expression and enzymic activity of ecto 5′-nucleotidase in the human male genital tract. Biol Reprod 59: 190-196. (Pubitemid 28304371)
80. Kramer G, Mitteregger D, Marberger M, (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 51: 1202-1216. (Pubitemid 46436310)
81. Kurokawa Y, Kojima K, Kanayama H, Kagawa S, Minami K, Nakaya Y, (1998). Activation of the Ca2+-activated K+ channel via protein kinase A-dependent phosphorylation in human prostatic smooth muscle cells. Int J Urol 5: 482-486. (Pubitemid 28488207)
82. Lang RJ, Mulholland E, Exintaris B, (2004). Characterization of the ion channel currents in single myocytes of the guinea pig prostate. J Urol 172: 1179-1187. (Pubitemid 39096496)
83. Langenstroer P, Tang R, Shapiro E, Divish B, Opgenorth T, Lepor H, (1993). Endothelin-1 in the human prostate: tissue levels, source of production and isometric tension studies. J Urol 150: 495-499. (Pubitemid 23215911)
84. Langenstroer P, Tang R, Divish B, Opgenorth T, Shapiro E, Lepor H, (1997). Endothelins in canine genitourinary tissues. J Urol 157: 1044-1048. (Pubitemid 27066314)
85. Lau WA, Pennefather JN, (1998). Muscarinic receptor subtypes in the rat prostate gland. Eur J Pharmacol 343: 151-156. (Pubitemid 28138597)
86. Lau WA, Ventura S, Pennefather JN, (1998). Pharmacology of neurotransmission to the smooth muscle of the rat and the guinea-pig prostate glands. J Auton Pharmacol 18: 349-356. (Pubitemid 29022762)
87. Lau WA, Cox SL, Pennefather JN, Mitchelson FJ, (1999). Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland. Br J Pharmacol 127: 1091-1098. (Pubitemid 29326630)
88. Lau WA, Pennefather JN, Mitchelson FJ, (2000). Cholinergic facilitation of neurotransmission to the smooth muscle of the guinea-pig prostate gland. Br J Pharmacol 130: 1013-1020. (Pubitemid 30453535)
89. Lee HY, Bardini M, Burnstock G, (2000). P2X receptor immunoreactivity in the male genital organs of the rat. Cell Tissue Res 300: 321-330. (Pubitemid 30333184)
90. Lepor H, (2007). Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol 9: 181-190.
91. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M, (1992). Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75: 207-212.
92. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M, (1999). The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140: 5250-5256.
93. Liu CM, Lo YC, Wu BN, Wu WJ, Chou YH, Huang CH, et al,. (2007). cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy. Prostate 67: 1397-1410.
94. Longhurst PA, Schwegel T, Folander K, Swanson R, (1996). The human P2x1 receptor: molecular cloning, tissue distribution, and localization to chromosome 17. Biochim Biophys Acta 1308: 185-188. (Pubitemid 26290675)
95. McConnel JD, (1995). Benign prostatic hyperplasia. J Urol 154: 402-403.
96. McVary KT, Monnig W, Camps JL, Jr, Young JM, Tseng LJ, van den Ende G, (2007a). Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177: 1071-1077. (Pubitemid 46216352)
97. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, et al,. (2007b). Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177: 1401-1407. (Pubitemid 46435965)
98. McVary KT, Siegel RL, Carlsson M, (2008). Sildenafil citrate improves erectile function and lower urinary tract symptoms independent of baseline body mass index or LUTS severity. Urology 72: 575-579.
99. Marshall I, Burt RP, Chapple CR, (1995). Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype. Br J Pharmacol 115: 781-786.
100. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB, (2001). Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 54: 935-944. (Pubitemid 32771319)
101. Miano R, De Nunzio C, Asimakopoulos AD, Germani S, Tubaro A, (2008). Treatment options for benign prostatic hyperplasia in older men. Med Sci Monit 14: RA94-R102.
102. Morelli A, Vignozzi L, Filippi S, Vannelli GB, Ambrosini S, Mancina R, et al,. (2007). BXL-628, a vitamin D receptor agonist effective in benign prostatic hyperplasia treatment, prevents RhoA activation and inhibits RhoA/Rho kinase signaling in rat and human bladder. Prostate 67: 234-247.
103. Moriyama N, Kurimoto S, Miyata N, Yamaura H, Yamazaki R, Sudoh K, et al,. (1996). Decreased contractile effect of endothelin-1 on hyperplastic prostate. Gen Pharmacol 27: 1061-1065. (Pubitemid 26345064)
104. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, et al,. (2000). Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403: 86-89. (Pubitemid 30038526)
105. Muramatsu I, Oshita M, Ohmura T, Kigoshi S, Akino H, Gobara M, et al,. (1994). Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. Br J Urol 74: 572-578. (Pubitemid 24348622)
106. Muramatsu I, Tanaka T, Suzuki F, Li Z, Hiraizumi-Hiraoka Y, Anisuzzaman AS, et al,. (2005). Quantifying receptor properties: the tissue segment binding method-a powerful tool for the pharmacome analysis of native receptors. J Pharmacol Sci 98: 331-339. (Pubitemid 41297006)
107. Muramatsu I, Morishima S, Suzuki F, Yoshiki H, Anisuzzaman AS, Tanaka T, et al,. (2008). Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout. Br J Pharmacol 155: 1224-1234.
108. Najbar-Kaszkiel AT, Di Iulio JL, Li CG, Rand MJ, (1997). Characterisation of excitatory and inhibitory transmitter systems in prostate glands of rats, guinea pigs, rabbits and pigs. Eur J Pharmacol 337: 251-258. (Pubitemid 27507791)
109. Narumiya S, Sugimoto Y, Ushikubi F, (1999). Prostanoid receptors: structures, properties, and functions. Physiol Rev 79: 1193-1226. (Pubitemid 29473315)
110. Nishimune A, Suzuki F, Yoshiki H, Morishima S, Muramatsu I, (2010a). Alpha 1-adrenoceptor pharmacome: alpha 1L-adrenoceptor and alpha 1A-adrenoceptor in the lower urinary tract. Int J Urol 17: 31-37.
111. Nishimune A, Suzuki F, Yoshiki H, Morishima S, Muramatsu I, (2010b). Identification of cysteine-rich epidermal growth factor-like domain 1alpha (CRELD1alpha) as a novel alpha1A-adrenoceptor-down-regulating protein and establishment of an alpha1L-adrenoceptor-expressing cell line. J Pharmacol Sci 113: 169-181.
112. Normandin DE, Lodge NJ, (1996). Pharmacological characterization of the isolated canine prostate. J Urol 155: 1758-1761. (Pubitemid 26126996)
113. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T, Denoux Y, et al,. (2009). Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 6: 836-847.
114. Oh SJ, Kim KM, Chung YS, Hong EK, Shin SY, Kim SJ, (2003). Ion-channel currents of smooth muscle cells isolated from the prostate of guinea-pig. BJU Int 92: 1022-1030. (Pubitemid 37548288)
115. Ohmura T, Sakamoto S, Hayashi H, Kigoshi S, Muramatsu I, (1993). Identification of alpha 1-adrenoceptor subtypes in the dog prostate. Urol Res 21: 211-215. (Pubitemid 23253439)
116. Palea S, Corsi M, Artibani W, Ostardo E, Pietra C, (1996). Pharmacological characterization of tachykinin NK2 receptors on isolated human urinary bladder, prostatic urethra and prostate. J Pharmacol Exp Ther 277: 700-705. (Pubitemid 27168978)
117. Pennefather JN, Lau WA, Chin C, Story ME, Ventura S, (1999). alpha(1L)-adrenoceptors mediate noradrenaline-induced contractions of the guinea-pig prostate stroma. Eur J Pharmacol 384: 25-30.
118. Preston A, Lau WA, Pennefather JN, Ventura S, (2000). Effects of adenine nucleosides and nucleotides on neuromuscular transmission to the prostatic stroma of the rat. Br J Pharmacol 131: 1073-1080.
119. Preston A, Frydenberg M, Haynes JM, (2004). A1 and A2A adenosine receptor modulation of alpha 1-adrenoceptor-mediated contractility in human cultured prostatic stromal cells. Br J Pharmacol 141: 302-310. (Pubitemid 38250900)
120. Purvis K, Rui H, Gordeladze JO, Attramadal H, (1986). Hormonal activation of the adenylyl cyclases of the rat and human prostate gland. Prostate 8: 11-24. (Pubitemid 16153833)
121. Ramsay D, Carr IC, Pediani J, Lopez-Gimenez JF, Thurlow R, Fidock M, et al,. (2004). High-affinity interactions between human alpha1A-adrenoceptor C-terminal splice variants produce homo- and heterodimers but do not generate the alpha1L-adrenoceptor. Mol Pharmacol 66: 228-239. (Pubitemid 38989479)
122. Raschack M, Gock S, Unger L, Hahn A, Amberg W, Jansen R, et al,. (1998). LU 302 872 and its racemate (LU 224 332) show balanced endothelin-A/B receptor affinity, high oral activity, and inhibit human prostate tissue contractions. J Cardiovasc Pharmacol 31 (Suppl. 1): S241-S244. (Pubitemid 128709918)
123. Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S, (2003). Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 170: 2517-2522. (Pubitemid 37414047)
124. Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, et al,. (2011). LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71: 736-747.
125. Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA, (2003). A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 6: 315-323. (Pubitemid 38088195)
126. Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L, (2008). Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 180: 1228-1234.
127. Rokosh DG, Simpson PC, (2002). Knockout of the alpha 1A/C-adrenergic receptor subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc Natl Acad Sci USA 99: 9474-9479. (Pubitemid 34764638)
128. Roosen A, Blake-James BT, Wood D, Fry CH, (2009). Clinical and experimental aspects of Adreno-muscarinic synergy in the bladder base and prostate. Neurourol Urodyn 28: 938-943.
129. Ruiz-Llorente L, Sanchez MG, Carmena MJ, Prieto JC, Sanchez-Chapado M, Izquierdo A, et al,. (2003). Expression of functionally active cannabinoid receptor CB1 in the human prostate gland. Prostate 54: 95-102. (Pubitemid 36120325)
130. Ruiz-Llorente L, Ortega-Gutierrez S, Viso A, Sanchez MG, Sanchez AM, Fernandez C, et al,. (2004). Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br J Pharmacol 141: 457-467. (Pubitemid 38297008)
131. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC, (2002). Sildenafil influences lower urinary tract symptoms. BJU Int 90: 836-839. (Pubitemid 36693615)
132. Saita Y, Yazawa H, Koizumi T, Morita T, Tamura T, Takenaka T, et al,. (1998). Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells. Eur J Pharmacol 349: 123-128. (Pubitemid 28270665)
133. Salamoussa A, Lau WA, Pennefather JN, Ventura S, (2000). The contractile effects of endothelins on the smooth muscle of the rat prostate gland. Eur J Pharmacol 403: 139-145.
134. Scarpa RM, (2001). Lower urinary tract symptoms: what are the implications for the patients? Eur Urol 40 (Suppl. 4): 12-20. (Pubitemid 34062884)
135. Schulman CC, (2003). Lower urinary tract symptoms/benign prostatic hyperplasia: minimizing morbidity caused by treatment. Urology 62: 24-33. (Pubitemid 41113201)
136. Sciarra A, Di Silverio F, Salciccia S, Autran Gomez AM, Gentilucci A, Gentile V, (2007). Inflammation and chronic prostatic diseases: evidence for a link? Eur Urol 52: 964-972. (Pubitemid 47332058)
137. Sciarra A, Mariotti G, Salciccia S, Gomez AA, Monti S, Toscano V, et al,. (2008). Prostate growth and inflammation. J Steroid Biochem Mol Biol 108: 254-260. (Pubitemid 351179630)
138. Seok YM, Baek I, Kim YH, Jeong YS, Lee IJ, Shin DH, et al,. (2008). Isoflavone attenuates vascular contraction through inhibition of the RhoA/Rho-kinase signaling pathway. J Pharmacol Exp Ther 326: 991-998.
139. Shafik A, Shafik I, el-Sibai O, (2005). Identification of c-kit-positive cells in the human prostate: the interstitial cells of Cajal. Arch Androl 51: 345-351. (Pubitemid 41190669)
140. Shapiro E, Hartanto V, Lepor H, (1992). The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 21: 297-307. (Pubitemid 23045292)
141. Shibata K, Hirasawa A, Moriyama N, Kawabe K, Ogawa S, Tsujimoto G, (1996). Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy. Br J Pharmacol 118: 1403-1408. (Pubitemid 26248791)
142. Siejka A, Schally AV, Block NL, Barabutis N, (2010). Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. BJU Int 106: 1382-1388.
143. Stacey P, Rulten S, Dapling A, Phillips SC, (1998). Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 247: 249-254. (Pubitemid 28420808)
144. Stamatiou K, (2009). Management of benign prostatic hypertrophy-related urinary retention: current trends and perspectives. Urol J 6: 237-244.
145. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E, (2008). A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 53: 1236-1244.
146. Sudoh K, Inagaki O, Honda K, (1997). Responsiveness of smooth muscle in the lower urinary tract of rabbits to various agonists. Gen Pharmacol 28: 629-631. (Pubitemid 27156930)
147. Sui GP, Wu C, Fry CH, (2004). Ca2+ currents in smooth muscle cells isolated from human prostate. Prostate 59: 275-281. (Pubitemid 38509760)
148. Suzuki F, Taniguchi T, Takauji R, Murata S, Muramatsu I, (2000). Splice isoforms of alpha(1a)-adrenoceptor in rabbit. Br J Pharmacol 129: 1569-1576.
149. Tainio H, (1995). Peptidergic innervation of the human prostate, seminal vesicle and vas deferens. Acta Histochem 97: 113-119.
150. Takahashi R, Nishimura J, Seki N, Yunoki T, Tomoda T, Kanaide H, et al,. (2007). RhoA/Rho kinase-mediated Ca2+ sensitization in the contraction of human prostate. Neurourol Urodyn 26: 547-551. (Pubitemid 47036144)
151. Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H, (1995). Effects of nitric oxide on human and canine prostates. Urology 45: 440-446.
152. Tarter TH, Vaughan ED, Jr, (2006). Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia. Curr Pharm Des 12: 775-783.
153. Teng CM, Guh JH, Ko FN, (1994). Functional identification of alpha 1-adrenoceptor subtypes in human prostate: comparison with those in rat vas deferens and spleen. Eur J Pharmacol 265: 61-66.
154. Testa R, Guarneri L, Ibba M, Strada G, Poggesi E, Taddei C, et al,. (1993). Characterization of alpha 1-adrenoceptor subtypes in prostate and prostatic urethra of rat, rabbit, dog and man. Eur J Pharmacol 249: 307-315.
155. Testa R, Guarneri L, Taddei C, Poggesi E, Angelico P, Sartani A, et al,. (1996). Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther 277: 1237-1246. (Pubitemid 27167133)
156. Thorpe A, Neal D, (2003). Benign prostatic hyperplasia. Lancet 361: 1359-1367. (Pubitemid 36514874)
157. Tokanovic S, Malone DT, Ventura S, (2007). Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. Br J Pharmacol 150: 227-234. (Pubitemid 46160613)
158. Tokanovic S, White CW, Malone DT, Exintaris B, Ventura S, (2010). Characterisation of the prostanoid receptor mediating inhibition of smooth muscle contractility in the rat prostate gland. Naunyn Schmiedebergs Arch Pharmacol 381: 321-328.
159. Tseng-Crank J, Kost T, Goetz A, Hazum S, Roberson KM, Haizlip J, et al,. (1995). The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. Br J Pharmacol 115: 1475-1485.
160. Tsujii T, Azuma H, Yamaguchi T, Oshima H, (1992). A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J Pharmacol 107: 803-807.
161. Tsukamoto T, Masumori N, Rahman M, Crane MM, (2007). Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally. Int J Urol 14: 321-324 discussion 325. (Pubitemid 46669038)
162. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A, (2010). Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 28: 17-22.
163. Uckert S, Kuthe A, Jonas U, Stief CG, (2001). Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166: 2484-2490. (Pubitemid 33065340)
164. Uckert S, Hedlund P, Andersson KE, Truss MC, Jonas U, Stief CG, (2006). Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 50: 1194-1207. (Pubitemid 44692918)
165. Van der Aa F, Roskams T, Blyweert W, De Ridder D, (2003). Interstitial cells in the human prostate: a new therapeutic target? Prostate 56: 250-255. (Pubitemid 36988745)
166. Ventura S, Lau WA, Buljubasich S, Pennefather JN, (2000a). Species differences in the actions of sensory neuropeptides on contractility of the smooth muscle of the rat and guinea-pig prostate. Clin Exp Pharmacol Physiol 27: 917-921.
167. Ventura S, Lau WA, Buljubasich S, Pennefather JN, (2000b). Calcitonin gene-related peptide (CGRP) inhibits contractions of the prostatic stroma of the rat but not the guinea-pig. Regul Pept 91: 63-73.
168. Ventura S, Dewalagama RK, Lau LC, (2003). Adenosine 5′-triphosphate (ATP) is an excitatory cotransmitter with noradrenaline to the smooth muscle of the rat prostate gland. Br J Pharmacol 138: 1277-1284. (Pubitemid 36543125)
169. Walden PD, Ittmann M, Monaco ME, Lepor H, (1998). Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. Prostate 34: 241-250. (Pubitemid 28149868)
170. Waldkirch E, Uckert S, Sigl K, Langnaese K, Richter K, Stief CG, et al,. (2010). Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4. Urology 76: 514-518.
171. Wasilenko WJ, Cooper J, Palad AJ, Somers KD, Blackmore PF, Rhim JS, et al,. (1997). Calcium signaling in prostate cancer cells: evidence for multiple receptors and enhanced sensitivity to bombesin/GRP. Prostate 30: 167-173. (Pubitemid 27149275)
172. Watts SW, Cohen ML, (1991). Effect of bombesin, bradykinin, substance P and CGRP in prostate, bladder body and neck. Peptides 12: 1057-1062.
173. Webb ML, Chao CC, Rizzo M, Shapiro RA, Neubauer M, Liu EC, et al,. (1995). Cloning and expression of an endothelin receptor subtype B from human prostate that mediates contraction. Mol Pharmacol 47: 730-737.
174. Weisser H, Behnke B, Helpap B, Bach D, Krieg M, (1997). Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol 31: 97-101. (Pubitemid 27058112)
175. White CW, Short JL, Haynes JM, Evans RJ, Ventura S, (2010). The residual nonadrenergic contractile response to nerve stimulation of the mouse prostate is mediated by acetylcholine but not ATP in a comparison with the mouse vas deferens. J Pharmacol Exp Ther 335: 489-496.
176. Wilson JD, (1980). The pathogenesis of benign prostatic hyperplasia. Am J Med 68: 745-756. (Pubitemid 10096042)
177. Witte LP, Chapple CR, de la Rosette JJ, Michel MC, (2008). Cholinergic innervation and muscarinic receptors in the human prostate. Eur Urol 54: 326-334.
178. Yazawa H, Honda K, (1993). Alpha 1-adrenoceptor subtype in the rat prostate is preferentially the alpha 1A type. Jpn J Pharmacol 62: 297-304. (Pubitemid 23252166)
179. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K, (2000). Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expression. J Biol Chem 275: 31469-31479.
180. Zaichick VY, Sviridova TV, Zaichick SV, (1996). Zinc concentration in human prostatic fluid: normal, chronic prostatitis, adenoma and cancer. Int Urol Nephrol 28: 687-694. (Pubitemid 27110256)
181. Zenzmaier C, Sampson N, Pernkopf D, Plas E, Untergasser G, Berger P, (2010). Attenuated proliferation and trans-differentiation of prostatic stromal cells indicate suitability of phosphodiesterase type 5 inhibitors for prevention and treatment of benign prostatic hyperplasia. Endocrinology 151: 3975-3984.
182. Zhao C, Kim SH, Lee SW, Jeon JH, Kang KK, Choi SB, et al,. (2011). Activity of phosphodiesterase type 5 inhibitors in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. BJU Int in press.